{
  "trial_id": "NCT03264131",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age \u2265 18 years at the time of consent.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Histological confirmation of biopsy-proven peripheral T-cell leukemia/lymphoma consistent with ATLL.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Positive human T-lymphotropic virus-1 (HTLV-1) antibody testing with confirmatory testing via Western blot, enzyme-linked immunosorbent assay (ELISA), or molecular testing (PCR).",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Documented negative serologic testing for human immunodeficiency virus (HIV).",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Demonstrate adequate organ function as defined below; all screening labs to be obtained within three days prior to study treatment.",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Females of childbearing potential must have a negative serum pregnancy test within three days (72 hours) prior to initiating study treatment.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Male patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception starting with the first dose of study therapy through 24 weeks (6 months) after the last dose of study therapy.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "As determined by the enrolling physician or protocol designee, willingness and ability to comply with the requirements and restrictions listed in the informed consent form.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Has a known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least five years.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Previous exposure to brentuximab vedotin (BV).",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.",
  "_meta": {
    "topic_id": "74",
    "trial_id": "NCT03264131",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}